Good morning, everyone. I'd like to call to order MiNK Therapeutics 2026 Virtual Annual Meeting of Stockholders. I'm Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. Our Chairman, Dr. Garo Armen, has appointed me to preside over this meeting. With me today is Robinson Hill, Assistant Secretary of the meeting, Stefanie Nacar, Head of Corporate Communications and Investor Relations, and the following members of our Board of Directors, Garo Armen, Chairman, Peter Bonner, Brian Corvese, Barbara Ryan, John Holcomb, and Ulf Winberg, among others. I'd like to thank them and each of you, whether participating by proxy in advance of the meeting or online today, for your time and commitment to MiNK. I'd now like to turn things over to Stefanie to conduct the formal portion of our meeting. Stefanie? Good morning. Thank you, Jen, and welcome to all of our stockholders. We will now begin the formal portion of the annual meeting as set forth in the notice of annual meeting and proxy statement. I have received an affidavit of distribution from Broadridge Financial Solutions, Inc. That notice of this meeting was furnished by the company on or about April 30, 2026, to holders of record of common stock as of the close of business on April 23, 2026, the record date for this meeting. The Board of Directors has appointed Terrence Hassett as the Inspector of Elections for this meeting. Mr. Hassett has taken and subscribed the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of this meeting. Mr. Hassett's function is to decide upon the qualifications of the voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. As of June 16, 2026, I have been informed by Mr. Hassett that proxies have been received for at least 3,277,906 of the 4,981,899 shares of common stock outstanding on the record date, which represents approximately 66% of the total number of outstanding shares. Therefore, I declare that a quorum is present. A list of stockholders as of the record date is available for inspection by our stockholders by navigating to the bottom blue footer of your screen and clicking on the link labeled "Registered Shareholders List." During the meeting, stockholders may access the Q&A feature by clicking on the button labeled Q&A in the bottom right-hand corner of the screen. Questions pertinent to matters will be collected and answered following the meeting. The matters to be voted on at today's meeting are set forth in the company's proxy statement. The company has not received notice from any of its stockholders of any additional matters to be considered at today's meeting. Therefore, no additional matters will be voted on. Let me briefly describe the voting procedures. You may vote your shares during the meeting through the web portal by following the instructions listed. If you have previously voted by proxy, you do not need to vote again unless you wish to change your vote. If you have not already voted or you wish to change your vote, please follow the instructions on the web portal for how to submit your vote. No votes, ballots, or proxies, or revocation of changes to votes, ballots, or proxies will be accepted after the polls are closed. I now declare the polls open for each matter to be voted on at this annual meeting. Proposal number one. The first item on the agenda is to elect Garo Armen, Barbara Ryan, and John Holcomb as Class II directors, each for a term of three years, expiring at the 2029 annual meeting of stockholders. Their qualifications are described on pages seven and eight of the proxy statement, and the board of directors unanimously recommends that stockholders vote in favor of Dr. Buell's and Mr. Winberg's elections. I'm sorry, that was Dr. Armen, Barbara Ryan, and John Holcomb's election. Proposal two, the second item on the agenda is to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. A detailed description of the proposal can be found on pages 25 of the proxy statement. The board of directors unanimously recommends that stockholders vote in favor of this proposal. I will now keep the voting open for a few moments before closing the polls. The polls are now closed. I will now deliver the report on the results of the vote obtained from the Inspector of Elections. The report of the Inspector of Election covering the proposals presented at this meeting is as follows. Proposal one, the proposal to elect Garo Armen, Barbara Ryan, and John Holcomb as Class II directors, each for a term of three years expiring at the 2029 annual meeting of stockholders is carried. Proposal number two, the proposal to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026 is carried. We expect to report our preliminary voting results, or if available to us on a timely basis, our final voting results on our current report on Form 8-K to be filed with the SEC within four business days after the end of the meeting. If not earlier reported, we expect to report our final voting results in an amendment to our Form 8-K within four business days after the final results are known to us. That concludes the formal portion of the meeting. Before I turn things over to Jen, I would like to note that the remainder of this meeting will include forward-looking statements, including statements regarding clinical development and regulatory plans and timelines and strategy. These statements are subject to risks and uncertainties. We refer to our SEC filings for more details on these risks. Jen? Thank you, Stefanie. Good morning, everyone. Thank you for joining us. I want to begin with a simple observation. The most important advances in medicine often begin with a different way of looking at the problem. For decades, medicine has largely focused on three approaches, killing pathogens, suppressing inflammation, cutting out or chemotherapeutically burning tumors. While these approaches have transformed treatments and saved lives, millions of patients continue to suffer because the underlying problem is not simply infection, inflammation, or cancer. The underlying problem is that the immune system itself has lost coordination. Patients can no longer clear infection, no longer regulate inflammation, repair injured tissue, or mount effective anticancer responses. At MiNK, we believe the next frontier is helping the immune system recover its ability to heal. That's the foundation of our strategy. Over the last 12 months, we've begun demonstrating that strategy through execution. Today, our strategy is a result of several years of clinical, translational, and scientific learning. What we've come to understand is that many of the most difficult diseases in medicine are connected by a common biological problem. In cancer, the immune system can no longer recognize or eliminate tumor cells. In severe infection, the immune system becomes exhausted or unable to clear pathogens. In respiratory distress and critical illness, the immune system loses the ability to coordinate inflammation, tissue repair, and recovery. In transplantation, the immune system must simultaneously protect the patient while avoiding damage to healthy tissues. These are different diseases. The same underlying challenge, loss of immune coordination. This insight has fundamentally shaped our strategy and our mission. We no longer view these as separate therapeutic areas. We view them as different manifestations of immune dysfunction. Over the last several years, our clinical translational work has consistently reinforced the same conclusion. The question is often not whether the immune system is too active or too weak. The question is whether it's functioning appropriately. That understanding has allowed us to focus our efforts where we believe iNKT biology can have the greatest impact. That is the thread connecting everything we do, and it's also why ARDS has emerged as our lead development program. Acute respiratory distress syndrome, acute respiratory failure, hypoxemic pneumonia. These represent one of the clearest examples of catastrophic immune dysfunction and one of the largest areas of unmet medical need. In fact, these diseases impact more than 300,000 lives annually, with more than half succumbing to their disease, dying from their disease. During the pandemic, we demonstrated more than 70%, in some cases over 80% survival rates. Those data are published. These rates compared very favorably to what we observed in in-hospital controls of around 10%-20% in the same patient population. We identified and are validating biomarkers of response, those most likely to predict patients who will benefit from cell therapy. Going forward, our trials are designed to demonstrate that restoring immune competence may change outcomes for patients with respiratory distress. If we can successfully do so, we believe this becomes one of the clearest demonstrations of what our platform can achieve across multiple disease settings. One year ago, we had a compelling scientific thesis. Today, we have an active randomized phase II trial designed to move into a seamless phase III trial in patients with severe hypoxemic pneumonia and respiratory failure. Published evidence of immune restoration in critically ill patients. We also have a platform that can deliver native cells as well as those engineered to target very specific disease settings. We've established partnerships with C-Further and LifeArc for advancing our pediatric medicines. We've demonstrated that we have a deployable cellular medicine being delivered internationally. In short, we've moved from hypothesis to proof points, and I'm going to walk you through what we've delivered. First, we've advanced 797 into randomized phase II clinical validation in severe pneumonia, acute lung injury, respiratory failure. In May, we initiated that study C13-02 in Lviv, Ukraine. We received authorization from the Ministry of Health of Ukraine and activated First Lviv Medical Union and UNBROKEN and dosed our first patients in the trial. The achievement is important for a couple of reasons. Clinically, it addresses one of the largest unmet needs in medicine. Acute respiratory illness remains the leading cause of mortality in critical care. There are no approved therapies that reliably reduce mortality. Operationally, this trial demonstrates deployability. We're conducting a randomized trial in a country at war. We've shipped product internationally, activated sites, trained investigators, established logistics, and begun treating critically ill patients under conditions many organizations would consider impossible. Importantly, these patients include individuals suffering from severe infections, multi-drug resistant pathogens, precisely the population where new therapeutic approaches are urgently needed. Agent 797 can be deployed successfully in this environment, and we believe it can now be deployed anywhere. Second, we strengthened the pulmonary disease thesis. At the American Thoracic Society meeting, Dr. Terese Hammond presented and published that critically ill patients with disseminated coccidioides infection, bacterial co-pathogens, and ARDS can be helped with a combination of immune therapies, including Agent 797. We observe pathogen suppression, immune recruitment into the lung, regulation of inflammation, and activation of tissue repair pathways after dosing with our iNKT cells. More importantly, these findings support a broader hypothesis. Restoring immune competence may improve outcomes across severe pulmonary diseases where infection, inflammation, and tissue injury intersect. We are now prospectively evaluating that biology in our randomized phase II trial. Third, we demonstrated why iNKT biology is fundamentally differentiated. At the American Society of Gene & Cell Therapy Conference in Boston this year, we presented findings showing context-dependent activity of Agent 797. That means the product derived from the same donor, manufactured using the same process, produced from our manufacturing facility in Lexington, Massachusetts, and delivered to patients with different diseases. This product from the same donor produced different immune outputs in different disease environments. In solid tumor cancer, the response was consistent with anti-tumor immune activation, including a substantial pro-inflammatory response to recruit memory cells and NK cells to eliminate the tumor. In respiratory distress, the response was different. It was consistent with immune regulation and lung injury recovery. We saw that these cells actually dampened pro-inflammatory cytokines, improved the ability of the patient to respond. Most cell therapies are engineered to perform a single function, but donor-derived iNKT cells are different. They're thymic-educated immune cells that respond to the biologic environment they encounter. In cancer, they activate anti-tumor immunity. In inflammatory diseases, they dampen harmful inflammation. They restore immune balance. That's what we mean when we say that these cells read the room or deliver context-dependent outcomes. Fourth, we continued advancing oncology. At the American Association for Cancer Research earlier this year, we presented data supporting the use of 797 in refractory solid tumors, specifically in patients with relapsed refractory gastroesophageal cancer. We demonstrated evidence of immune remodeling, disease control, and durable responses prolong survival when we've integrated 797 in combination with checkpoint-based strategies. In this population, these are patients who have failed chemotherapy, have failed approved anti-PD-1 therapy, a population with survival expectations of six months, we observed more than 77% of patients had disease control, in a cohort of patients with survival exceeding 20 months compared to expectations of six months. We also publicly disclosed a complete remission of a patient in refractory metastatic germ cell tumors published in Nature's Oncogene. This patient had failed multiple prior therapies. These findings reinforce a consistent theme. When the immune system fails to control disease, iNKT cells may help restore effective immune responses. Fifth, we've expanded our program platform into patients undergoing hematopoietic stem cell transplantation. We are preparing to dose our first patients into a phase I study evaluating agenT-797 in preventing graft versus host disease at the University of Wisconsin–Madison. This program is supported through grant funding through the NIH STTR funding mechanism. The clinical trial is supported through philanthropic support. This is another setting where immune regulation and immune restoration must coexist. We believe iNKT cells may be uniquely suited to that challenge. Sixth, we've advanced our engineered platform. One of the most important developments this year was our collaboration with C-Further, created by LifeArc, Cancer Research Horizons, and Great Ormond Street Hospital Charity. C-Further selected MiNK's PRAME-directed TCR iNKT therapy following extensive scientific review. Our program was the first of two programs to be selected for advancement. Scientifically, this validates our platform. Operationally, it accelerates development of our TCR PRAME therapy. Financially, it provides non-dilutive funding to advance the program and meaningful downstream double-digit royalty economics that preserve long-term shareholder participation. This partnership allows us to advance potentially transformative engineered therapy while maintaining capital discipline. Seventh, we've established our named patient access program. This is the first we're talking about it publicly. This is a critical milestone for both patients as well as MiNK Therapeutics. Patients facing life-threatening diseases often cannot wait for traditional development timelines. Through our named patient access program, physicians can request access to agenT-797, our off-the-shelf allogeneic iNKT cell therapy for patients with serious diseases, serious unmet medical needs. This creates a pathway for treatment while clinical development continues in parallel. Importantly, these programs can operate through reimbursement, direct payment, or other sustainable access mechanisms, allowing patients to receive therapy while supporting continued development of the platform. We've already begun activating this framework internationally, including our first patient coming into the program is in Brazil under the leadership of Dr. Antonio Buzaid, one of Latin America's most respected oncologists. For us, this program represents more than access. It represents physician confidence in our biology, patient demand. It represents an opportunity to establish sustainable pathways that support both patients and long-term platform development. As we continue to expand globally, we expect these programs to become increasingly important component of our strategy. Finally, I'll speak directly about our capital. Innovation really matters, particularly with the technology that we're working with. Capital allocation is critical. Over the last year, we've deliberately pursued a strategy designed to maximize progress while minimizing dilution. The University of Wisconsin prevention of acute GvHD study is externally funded. Our PRAME TCR iNKT program advancing in pediatric cancers is externally funded. Government agencies continue to evaluate opportunities in pulmonary disease, trauma, critical illness, biodefense, and deployable biologics to help us advance our program in these areas. Our patient access programs create pathways that support both patients and development. This approach allows us to broaden the platform, generate data, and advance multiple programs while preserving flexibility for our shareholders. That discipline is one of the reasons we've accomplished so much over the last 12 months. Today, we are advancing quickly. We are preparing the foundation for commercial readiness as our randomized phase II into a seamless phase III will be in front of the agency for validation of our development plans, our timelines, our CMC readiness for commercial, as this is a disease in which endpoint readouts are very quick. We expect to be presenting data from the initial patients dosed in our phase II trial at a major conference in the second half of this year, as well as data presentations in GvHD, as well as some innovative components of our platform at three major conferences in the second half of this year. We're building a company at the intersection of pulmonary medicine, immune restoration, cancer, transplantation with deployable biologic solutions and engineered cell therapy. There's work ahead, but over the last year, we've moved from vision to execution. We've dosed countless patients, we've initiated randomized trials, we've published, we've partnered, we've expanded access, we've advanced our engineered programs, and we've attracted meaningful external validation. The diseases we seek to address that we discussed today share a common thread. These are diseases of immune dysfunction. We believe the future may not be defined by immune suppression or immune stimulation alone. It will be defined by immune restoration. MiNK is building the platform to lead that future. To our patients, we're moving as quickly and responsibly as we can. To our collaborators, thank you for helping us build this vision. To our shareholders, thank you for your continued support. Your confidence have been invaluable. We understand the responsibility that comes with it, and we look forward to sharing our continued progress in the months ahead, including data readouts at three major upcoming conferences in the second half of this year. Thank you. The meeting has now concluded. Thank you for your participation. You may now disconnect.